Susquehanna Fundamental Investments LLC Purchases New Shares in Novavax, Inc. (NASDAQ:NVAX)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 343,414 shares of the biopharmaceutical company's stock, valued at approximately $2,761,000. Susquehanna Fundamental Investments LLC owned approximately 0.21% of Novavax as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Novavax by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock worth $126,439,000 after acquiring an additional 296,181 shares during the last quarter. Shah Capital Management boosted its holdings in Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after purchasing an additional 1,333,305 shares during the last quarter. Geode Capital Management LLC grew its position in Novavax by 4.4% in the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after purchasing an additional 155,206 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Novavax by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,365,414 shares of the biopharmaceutical company's stock valued at $10,978,000 after buying an additional 39,906 shares during the last quarter. Finally, TSP Capital Management Group LLC lifted its position in shares of Novavax by 0.6% during the 4th quarter. TSP Capital Management Group LLC now owns 1,358,565 shares of the biopharmaceutical company's stock worth $10,923,000 after buying an additional 7,700 shares in the last quarter. Institutional investors own 53.04% of the company's stock.

Novavax Price Performance

NASDAQ NVAX remained flat at $6.41 during trading on Friday. 3,628,219 shares of the company's stock traded hands, compared to its average volume of 8,383,053. The stock has a market capitalization of $1.03 billion, a PE ratio of -2.84, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. The business's 50-day simple moving average is $7.01 and its 200 day simple moving average is $8.16. Novavax, Inc. has a 1-year low of $4.43 and a 1-year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same period in the previous year, the business earned ($1.44) earnings per share. On average, research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVAX. BTIG Research assumed coverage on Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 price target for the company. TD Cowen raised Novavax to a "hold" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.